OR WAIT null SECS
Pfizer announced that its investigational vaccine candidate for the treatment of Clostridium difficile has been granted the Fast Track designation from FDA.
Pfizer Inc. announced on Aug. 28 that FDA has granted Fast Track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate. Currently in Phase II clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis.
The FDA’s Fast Track approach is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address an unmet medical need.